Literature DB >> 25878116

Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Daniel P Leaman1, Jeong Hyun Lee2, Andrew B Ward2, Michael B Zwick3.   

Abstract

UNLABELLED: HIV-1 envelope glycoprotein (Env) spikes are prime vaccine candidates, at least in principle, but suffer from instability, molecular heterogeneity and a low copy number on virions. We anticipated that chemical cross-linking of HIV-1 would allow purification and molecular characterization of trimeric Env spikes, as well as high copy number immunization. Broadly neutralizing antibodies bound tightly to all major quaternary epitopes on cross-linked spikes. Covalent cross-linking of the trimer also stabilized broadly neutralizing epitopes, although surprisingly some individual epitopes were still somewhat sensitive to heat or reducing agent. Immunodepletion using non-neutralizing antibodies to gp120 and gp41 was an effective method for removing non-native-like Env. Cross-linked spikes, purified via an engineered C-terminal tag, were shown by negative stain EM to have well-ordered, trilobed structure. An immunization was performed comparing a boost with Env spikes on virions to spikes cross-linked and captured onto nanoparticles, each following a gp160 DNA prime. Although differences in neutralization did not reach statistical significance, cross-linked Env spikes elicited a more diverse and sporadically neutralizing antibody response against Tier 1b and 2 isolates when displayed on nanoparticles, despite attenuated binding titers to gp120 and V3 crown peptides. Our study demonstrates display of cross-linked trimeric Env spikes on nanoparticles, while showing a level of control over antigenicity, purity and density of virion-associated Env, which may have relevance for Env based vaccine strategies for HIV-1. IMPORTANCE: The envelope spike (Env) is the target of HIV-1 neutralizing antibodies, which a successful vaccine will need to elicit. However, native Env on virions is innately labile, as well as heterogeneously and sparsely displayed. We therefore stabilized Env spikes using a chemical cross-linker and removed non-native Env by immunodepletion with non-neutralizing antibodies. Fixed native spikes were recognized by all classes of known broadly neutralizing antibodies but not by non-neutralizing antibodies and displayed on nanoparticles in high copy number. An immunization experiment in rabbits revealed that cross-linking Env reduced its overall immunogenicity; however, high-copy display on nanoparticles enabled boosting of antibodies that sporadically neutralized some relatively resistant HIV-1 isolates, albeit at a low titer. This study describes the purification of stable and antigenically correct Env spikes from virions that can be used as immunogens.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25878116      PMCID: PMC4468504          DOI: 10.1128/JVI.03738-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  100 in total

Review 1.  Immunogenicity of HIV-1 envelope glycoprotein oligomers.

Authors:  Mattias N E Forsell; William R Schief; Richard T Wyatt
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

Review 2.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

Review 3.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

4.  Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Authors:  Katie J Doores; Dennis R Burton
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

7.  Few and far between: how HIV may be evading antibody avidity.

Authors:  Joshua S Klein; Pamela J Bjorkman
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

8.  Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Authors:  Georgia D Tomaras; Nicole L Yates; Pinghuang Liu; Li Qin; Genevieve G Fouda; Leslie L Chavez; Allan C Decamp; Robert J Parks; Vicki C Ashley; Judith T Lucas; Myron Cohen; Joseph Eron; Charles B Hicks; Hua-Xin Liao; Steven G Self; Gary Landucci; Donald N Forthal; Kent J Weinhold; Brandon F Keele; Beatrice H Hahn; Michael L Greenberg; Lynn Morris; Salim S Abdool Karim; William A Blattner; David C Montefiori; George M Shaw; Alan S Perelson; Barton F Haynes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

9.  Tyrosine bioconjugation through aqueous ene-type reactions: a click-like reaction for tyrosine.

Authors:  Hitoshi Ban; Julia Gavrilyuk; Carlos F Barbas
Journal:  J Am Chem Soc       Date:  2010-02-10       Impact factor: 15.419

Review 10.  HIV-1 neutralization: mechanisms and relevance to vaccine design.

Authors:  Michael B Zwick; Dennis R Burton
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581

View more
  16 in total

1.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

2.  Dense Array of Spikes on HIV-1 Virion Particles.

Authors:  Armando Stano; Daniel P Leaman; Arthur S Kim; Lei Zhang; Ludovic Autin; Jidnyasa Ingale; Syna K Gift; Jared Truong; Richard T Wyatt; Arthur J Olson; Michael B Zwick
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

3.  Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.

Authors:  Syna Kuriakose Gift; Daniel P Leaman; Lei Zhang; Arthur S Kim; Michael B Zwick
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

Review 4.  Evolution of B cell analysis and Env trimer redesign.

Authors:  Gunilla B Karlsson Hedestam; Javier Guenaga; Martin Corcoran; Richard T Wyatt
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

5.  Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer.

Authors:  Jeong Hyun Lee; Gabriel Ozorowski; Andrew B Ward
Journal:  Science       Date:  2016-03-04       Impact factor: 47.728

6.  Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes.

Authors:  Daniel P Leaman; Armando Stano; Yajing Chen; Lei Zhang; Michael B Zwick
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

7.  Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.

Authors:  Torben Schiffner; Natalia de Val; Rebecca A Russell; Steven W de Taeye; Alba Torrents de la Peña; Gabriel Ozorowski; Helen J Kim; Travis Nieusma; Florian Brod; Albert Cupo; Rogier W Sanders; John P Moore; Andrew B Ward; Quentin J Sattentau
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

8.  Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.

Authors:  Edurne Rujas; Naveed Gulzar; Koldo Morante; Kouhei Tsumoto; Jamie K Scott; José L Nieva; Jose M M Caaveiro
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

9.  Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies.

Authors:  Yu Feng; Karen Tran; Shridhar Bale; Shailendra Kumar; Javier Guenaga; Richard Wilson; Natalia de Val; Heather Arendt; Joanne DeStefano; Andrew B Ward; Richard T Wyatt
Journal:  PLoS Pathog       Date:  2016-08-03       Impact factor: 6.823

10.  Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers.

Authors:  Steven W de Taeye; Alba Torrents de la Peña; Andrea Vecchione; Enzo Scutigliani; Kwinten Sliepen; Judith A Burger; Patricia van der Woude; Anna Schorcht; Edith E Schermer; Marit J van Gils; Celia C LaBranche; David C Montefiori; Ian A Wilson; John P Moore; Andrew B Ward; Rogier W Sanders
Journal:  J Biol Chem       Date:  2017-12-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.